IJR News

Novo Nordisk licenses potential once-weekly obesity pill from Hengrui in $2.6B deal — 1dNovo Nordisk will pay Hengrui $300 million upfront, and up to $2.6 billion total, for HRS-1596, a GLP-1/GIP candidate aimed at once-weekly oral obesity dosing.

Dana Whitfield Spending billions on something still in trials feels like a gamble, but Novo must see real potential in that GLP-1 combo from Hengrui.

Libyan Agency Reports Seizing 100,000 Gaddafi-Faced Pills — Sep 13, 2026Libyan authorities seized about 100,000 pills molded with Muammar Gaddafi’s face and robes, described by Al Rada as ecstasy after a European sea shipment.

Rachel Meyers Hard to believe anyone would buy ecstasy stamped like that, but it shows how far some will go for novelty.

Eli Lilly Breaks Ground on $6.5B Houston Facility — Sep 21, 2026Eli Lilly broke ground Sept. 21, 2026 on a $6.5B Houston API plant to make Foundayo, its oral GLP-1 pill, with 600+ jobs as part of a $50B U.S. manufacturing push.

Maya Lindstrom Hope this oral GLP-1 pill becomes more affordable once production ramps up locally.

Report: Hayden Panettiere death probe examines fentanyl-laced oxycodone — Sep 14, 2026Hayden Panettiere, 36, reportedly died Aug. 16, 2026, in South Carolina after allegedly taking one fentanyl-laced oxycodone pill; toxicology pending, DEA investigating.

Dutch health institute warns Trump-shaped ecstasy pills contain dangerous PMMA — Aug 31, 2026The Trimbos Institute in the Netherlands issued a Red Alert warning over Trump-shaped ecstasy pills containing high levels of PMMA, a drug risk that can cause overheating, seizures, and potentially fatal outcomes, while urging people not to take them and to have drugs tested. The pills, appearing in multiple colors with Trump’s image and NL/Trump markings, were detected by the Drugs Information and Monitoring System across the country, with no deaths reported at the time of the warning.

Tom Gallagher PMMA takes way longer to hit than MDMA, so people redose thinking it's weak and that's when it turns deadly.

Most Influential Women in World HistoryYourlist — RankingFrom ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.

Panettiere rep says death investigation ongoing amid unverified reports — Sep 15, 2026Hayden Panettiere's death remains under investigation with toxicology results pending, and her representative has urged patience while dismissing unverified reports about potential drug involvement. Reports of a fentanyl-laced pill and a DEA search have circulated, but authorities have not confirmed a cause, as investigators continue to seek clarity on what happened.

Novo Nordisk launches Wegovy pill in Germany as Eli Lilly readies rival — Sep 1, 2026Novo Nordisk is rolling out Wegovy as an oral weight‑loss pill in Germany, the EU’s first market to receive the formulation after EU approval, with prices expected around €170–€280 and strong competition from Eli Lilly’s Foundayo on the horizon. The launch leverages Wegovy’s dominant position in the oral obesity market, while analysts weigh the impact of the tablet on growth, pricing, and payer access across Europe.

Tom Gallagher Curious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.

AstraZeneca Breast Cancer Trial Misses Key Goal — Sep 11, 2026AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.

Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.

Novartis MS pill beats Aubagio in two large phase 3 trials — Sep 1, 2026Novartis reported positive Phase 3 REMODEL-1 and REMODEL-2 results for the BTK inhibitor remibrutinib in relapsing multiple sclerosis, showing lower annualized relapse rate and meaningful reductions in disability progression versus teriflunomide and prompting worldwide regulatory filings. With remibrutinib already approved for chronic spontaneous urticaria as Rhapsido, the drug’s MS potential could become a major growth driver given its favorable safety profile and strong early sales signals.

Rachel Meyers Teriflunomide isn't the toughest comparator out there, would like to see how remibrutinib stacks up against some of the stronger existing MS drugs before getting too excited.